{"id":"cyp2c19-genotype-guided-p2y12-monotherapy","safety":{"commonSideEffects":[{"rate":null,"effect":"Bleeding (major and minor)"},{"rate":null,"effect":"Dyspnea"},{"rate":null,"effect":"Bradycardia"},{"rate":null,"effect":"Gastrointestinal bleeding"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"P2Y12 inhibitors (such as clopidogrel, prasugrel, or ticagrelor) are antiplatelet agents that block the P2Y12 adenosine diphosphate receptor on platelets. CYP2C19 is a key enzyme in the metabolism of some P2Y12 inhibitors, particularly clopidogrel. Genetic variants in CYP2C19 affect drug metabolism rates; poor metabolizers may have reduced drug efficacy, while ultra-rapid metabolizers may have increased bleeding risk. Genotype-guided therapy tailors P2Y12 monotherapy selection or dosing to individual metabolizer phenotype, improving clinical outcomes in cardiovascular disease management.","oneSentence":"CYP2C19 genotype-guided P2Y12 monotherapy uses genetic testing to select appropriate P2Y12 inhibitor dosing or choice based on individual cytochrome P450 2C19 metabolizer status, optimizing antiplatelet efficacy while reducing bleeding risk.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:29:31.917Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute coronary syndrome (ACS) and post-percutaneous coronary intervention (PCI) management in patients with known CYP2C19 genotype"},{"name":"Secondary prevention of thrombotic events in coronary artery disease"}]},"trialDetails":[{"nctId":"NCT06763744","phase":"PHASE4","title":"Genotype-Guided Abbreviated DAPT Versus Un-Guided De-escalation Therapy in Patients With ACS and HBR","status":"NOT_YET_RECRUITING","sponsor":"Samsung Medical Center","startDate":"2025-06-01","conditions":"Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI), High Bleeding Risk","enrollment":3000},{"nctId":"NCT05926271","phase":"PHASE2","title":"POPular GUILTY PILOT: Genotype-guided Clopidogrel Monotherapy","status":"RECRUITING","sponsor":"St. Antonius Hospital","startDate":"2023-07-15","conditions":"Acute Coronary Syndrome, CYP2C19 Polymorphism","enrollment":200},{"nctId":"NCT06283888","phase":"PHASE4","title":"CYP2C19 Genotype-Guided P2Y12 Receptor Inhibitor Selection After Complex Percutaneous Coronary Intervention","status":"RECRUITING","sponsor":"Zunyi Medical College","startDate":"2024-04-01","conditions":"ACS - Acute Coronary Syndrome, CYP2C19 Polymorphism","enrollment":1200},{"nctId":"NCT05773989","phase":"PHASE4","title":"Pharmacodynamic Outcomes in CCS Patients Treated With an Individualized Treatment Strategy","status":"UNKNOWN","sponsor":"St. Antonius Hospital","startDate":"2024-01-23","conditions":"Coronary Artery Disease, Platelet Reactivity","enrollment":88}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Ticagrelor","Prasugrel","Clopidogrel"],"phase":"marketed","status":"active","brandName":"CYP2C19 genotype guided P2Y12 monotherapy","genericName":"CYP2C19 genotype guided P2Y12 monotherapy","companyName":"St. Antonius Hospital","companyId":"st-antonius-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"CYP2C19 genotype-guided P2Y12 monotherapy uses genetic testing to select appropriate P2Y12 inhibitor dosing or choice based on individual cytochrome P450 2C19 metabolizer status, optimizing antiplatelet efficacy while reducing bleeding risk. Used for Acute coronary syndrome (ACS) and post-percutaneous coronary intervention (PCI) management in patients with known CYP2C19 genotype, Secondary prevention of thrombotic events in coronary artery disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}